London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
gix
are you thinking FF wouldn't get a bluecap for BP as well as one for platelets ?
W?
I am hoping that BH are building up some customers for their FF distribution throughout this year, so that come Q1 next year, they have multiple other businesses onboard, not just their own products.
Hence recent deal with bi-health starting 2023. Let's hope approval is quick. No worries about cash as we have plenty for now
So in my mind, it is submission by the end of June, then it goes for approvals, which should be "prompt" and in a "timely manner'. So perhaps by around September? A few months to get approvals and agree release of the info?
From the Sept final results RNS
By-Health currently expects to be in a position to complete the last of its eight studies and file its regulatory submission to the SAMR for Fruitflow in the first half of 2022.
We know that they are aiming towards submitting an "anti-platelet effect" type health claim to be included in the health claim register. None of the claims on the register fit fruitflow except the blood pressure one but IMO getting blue cap for this would limit the products ff could be used in. What happens after by-health get the appropriate health claim is anyone's guess atm.
gix
we aren't exactly sure what BH have/are applying for as it is. BP function plus new function, or just new function ?
W$
By-Health currently expects to be in a position to complete the last of its eight studies in 2022, and it will file its regulatory submission to the SAMR for Fruitflow at the appropriate time, seeking to obtain a new permitted health function claim for foods such as Fruitflow that can demonstrate an anti-platelet effect. If By-Health is successful in obtaining a new permitted health function claim, it is currently expected that this would result in some significant orders for Fruitflow, potentially at a multiple of current total sales values.
pressed reply to early :)
Hypothetical question, What happens if By-Health decide to take Fruitflow down the drug route?
Will by-health drop the supplement health claim in favour of a drug claim or will submissions/ claims run together?
Lets hope the SAMR does act "promptly" and in a "timely manner" although the timing of the submission is a little vague atm.
Hypothetical question, What happens if By-Health decide to take Fruitflow down the drug route?
Sphinx,
I am inferring that from this document, articles 19 to 24 in particular.
https://gkml-samr-gov-cn.translate.goog/nsjg/fgs/201908/t20190820_306117.html?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en
We know from the RNS that the scientific tests are performed by SAMR.
Dr Horrible you wrote “The approval is expected to be prompt”where did you read that , I’ve looked at the last few reports and can’t find it !
Kiev I’m not saying they are not selling ff+ only that to achieve the £21k increase in sells , the numbers we get doesn’t show the 34% increase , so that increase must be shown somewhere as it’s not showing in the order numbers we get !
Indeed.
"The Company’s Fruitflow+ Omega-3 direct selling business accounted for £76k of total revenue, a 34% increase in this business relative to the prior six month period (2020: £57k)."
Can't be. Intim figures for ff+ were up a fair bit
Thanks ws just. Checked and similar To you 3312 difference so no great uplift in orders ,i’ve a feeling our Chinese distributor orders must be recorded somewhere else!
sphinx
if you log into you account you can get a summary of orders with numbers. The delta number order has been pretty flat over last 6 months
My delta order numbers (rounded to nearest multiple of 10)
Jan-22 3300
Dec-21 3290
Nov-21 3380
Oct-21 3280
Sep-21 3060
Aug-21 3190
Jul-21 3220
Still unavailable at Amazon
https://www.amazon.co.uk/Fruitflow-Pressure-Supplement-Function-Circulation/dp/B07D6CTRZ9
W$
Anyone else not get an order number this month ,DD was taken and delivered yesterday but I didn’t get an email with the order number , just an oversight !!
No mention of Fruitflow that I have noticed but Asim has been busy wrt Covid.
Epidemiology, Transmission, and Molecular Immunopathology of SARS-CoV-2
https://pubmed.ncbi.nlm.nih.gov/35132593/
Origin and Structural Biology of Novel Coronavirus (SARS-CoV-2)
https://pubmed.ncbi.nlm.nih.gov/35132591/
A computational approach for molecular
characterization of Covaxin (BBV152) and its
ingredients for assessing its efficacy against
COVID-19
https://assets.researchsquare.com/files/rs-1332649/v1/fefdc6fb-b855-41d2-b2f1-07812c0f1115.pdf?c=1644355488
The following mentions WSTC
Tomatoes: An Extensive Review of the Associated Health
Impacts of Tomatoes and Factors That Can Affect
Their Cultivation
Many studies have shown tomato extracts to have platelet anti-aggregatory activity
in vitro and in vivo and possibly preventing thrombus formation [222,224–226,229–232]. A
study by Zhang et al. [233] investigated the impact of water-soluble tomato concentrate
(WSTC) on the platelet aggregation in Sprague Dawley rats. This study found that WSTC
inhibited adenosine diphosphate (ADP)-induced platelet aggregation in vitro and ex vivo
in the rats without affecting their coagulation system [233]. Platelet aggregation relies
on fibrinogen binding to the calcium-dependent glycoprotein (GP) IIb/IIIa complexes
found on platelets [234]. When platelets are activated by ADP, these GP IIb/IIIa complexes
bind with fibrinogen, leading to many platelets assembling and connecting to the same
fibrinogen strands and forming a clot [235]. Zhang et al. [233] found that WSTC increased
cytoskeleton stability and led to the inhibition of platelet aggregation.
https://scholar.google.co.uk/scholar_url?url=https://www.mdpi.com/2079-7737/11/2/239/pdf&hl=en&sa=X&d=11176106346757796582&ei=iCMHYs6eDbOSy9YPyOOPwAw&scisig=AAGBfm1GPCPyX8wD6EeUMBPWrWFXgarvdw&oi=scholaralrt&hist=tdTLxAIAAAAJ:16207114369439963800:AAGBfm35n33MpQVWZvEd33XHESBJwMWNdA&html=&pos=0&folt=kw
Fruitflow mentioned
https://www.news-medical.net/whitepaper/20211221/Discovering-why-human-intervention-studies-are-essential-to-human-studies.aspx
Won't be holding my breath on any of that, just top up as and when in the meantime...
Potential clinical applications of phytopharmaceuticals for the in-patient management of coagulopathies in COVID-19
Published yesterday, a brief mention
https://onlinelibrary.wiley.com/doi/full/10.1002/ptr.7408
Recent studies have focused on discovering natural products as active supplements or as replacements for ongoing synthetic antithrombotic drugs (Zhao et al., 2020). The active ingredients of natural products (e.g., extracts of traditional herbs and medicinal plants), the traditional system of medicine used in several countries (e.g., Chinese medicines), the Indian system of ancient medicine (Ayurveda), and functional foods have shown remarkable antithrombotic properties in vitro and in pre-clinical studies (Cordier et al., 2012; Gogoi, Ramani, Bhartari, Chattopadhyay, & Mukherjee, 2019; Li, Liang, & Sun, 2019; Memariani, Moeini, Hamedi, Gorji, & Mozaffarpur, 2018; O'Kennedy, Raederstorff, & Duttaroy, 2017; Sen & Chakraborty, 2017; Yamamoto et al., 2018). The significant advantages of using plant-derived natural products for therapeutic treatment have been realized because several of these compounds (as crude extracts or as partially purified plant extracts) are comprised of multiple components. Each component may target different factors in the coagulation cascade and their synergistic interactions may enhance their therapeutic efficacies (Gogoi et al., 2018,b, 2020). Moreover, numerous intriguing properties of natural products (e.g., rapid absorption when ingested by the oral route, marginal side-effect(s) in the gastrointestinal tract, and their non-immunogenicity) suggest their strong efficacy and safety (Fuentes & Palomo, 2014).
The SAMR submission should be complete by the end of the first half of the year, so by the end of June. The approval is expected to be prompt, whatever that means.
I would expect more info on the future relationship with DSM, at improved terms, and think there is more than a fair chance of commercial product launch (es) in the mainstream Chinese market with the marketing power of By Health to gain fast traction.
Had another scan through and stand by what I've said.
You expecting any news prior to results in Sept?
If you're not sure about that, then I suggest you review recent RNS's
looks like someone is accumulating to me,mmmmm